Amferia Annual General Meeting (AGM) Appoints Global Healthcare Leaders Randy Schwartz and Nikolaj Sørensen to Board of Directors
Amferia AB is pleased to announce the appointment of two new board members, Randy Schwartz and Nikolaj Sørensen, to help guide the company's next phase of global expansion. Following Amferia’s recent FDA De Novo classification, the company is actively preparing to accelerate its commercial entry into the US market. The addition of these two accomplished leaders brings targeted expertise in wound care commercialization, advanced medical devices, and international life science strategy—providing a powerful foundation for Amferia's continued growth.
Mölndal, Sweden—Following the FDA's grant of a De Novo classification for its antibacterial wound dressing, Amferia has strengthened its Board of Directors with the appointment of two experienced leaders in medtech and life sciences: Randy Schwartz and Nikolaj Sørensen.
Randy Schwartz is a senior healthcare executive and consultant with more than 40 years of experience driving growth, innovation, and market leadership in the medical technology, wound care, and skin health industries. As Principal of Med Market Consultants and GR Consulting Solutions, he advises start-up, emerging, and established healthcare companies on commercialization, market access, reimbursement, clinical strategy, business development, and global expansion. Previously, Randy held multiple executive leadership roles at Molnlycke Health Care, including Global Vice President of Medical & Professional Affairs, Vice President of Marketing, and Global Marketing Director, where he helped establish the company as a global leader in advanced wound care. He has extensive experience in strategic marketing, evidence development, product launches, M&A, and international market expansion, and currently serves on the Board of the Wound Care Collaborative Community, an FDA-recognized collaborative community focused on advancing innovation in wound care.
Nikolaj Sørensen has established an impressive track record within the international pharmaceutical and healthcare sectors, holding premier leadership positions such as; Managing Director of Pfizer AB, Senior Management roles across Pfizer Inc., Management Consultant at the Boston Consulting Group, and presently serves as the President and CEO of Orexo AB. Today, he utilizes his deep expertise in global corporate strategy to serve on the boards of pioneering enterprises. Nikolaj’s extensive knowledge in pharmaceutical commercialization and international scaling will be important for Amferia’s scale-up journey in both human and animal wound care.
The AGM also chose to re-elect Agneta Edberg (chair), Professor Martin Andersson, Anders Husmark and Henrik Jansson.
In February, Amferia was granted the De Novo Classification from the FDA, allowing the company to enter the U.S. market with a unique Class 2 medical device antibacterial dressing for advanced wound care, according to Amferia CEO and Co-Founder Anand Rajasekharan. The approval creates a new regulatory category for wound dressings, in which Amferia’s is the only approved product.
“The FDA approval has changed the landscape for Amferia,” said Rajasekharan. “After years of studies and development, now our attention turns to exploring how best to bring Amferia products to the U.S. market. With such a milestone accomplished, the next steps are key for Amferia’s success in the market. Therefore, it is an honor to work with Randy and Nikolaj, whose impressive knowledge of the field, especially US market access and guidance greatly strengthen Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the product launch in US following our FDA approval”
“The recruitment of Randy and Nikolaj is adding valuable US commercial experience since the FDA’s decision positions Amferia as a strategic partner for established wound care companies seeking next-generation antimicrobial solutions that align with evolving regulatory and safety expectations. Amferia’s technology is gaining notice as wound care companies now look to reduce their reliance on silver in their treatments. Silver has long been a mainstay as an antimicrobial in wound care, but commodification of silver, growing bacterial resistance to it, and changing regulations about when it should be applied have the industry looking for innovative new treatments”, Agneta Edberg, chair of the board concludes.
Separately, Amferia is readying clinical data to begin the approval process for human treatments within the European Union. The company expects heightened interest from industry partners and has built a family of patents designed to allow the expansion of its peptide-based technology beyond wound care over time.
The Race to Solve Global Antimicrobial Resistance
Antimicrobial resistance (AMR) is accelerating at a pace that threatens to become one of the leading causes of human mortality worldwide in coming decades. At least five million people are currently affected by infections caused by antibiotic resistance. In countries with a high incidence of resistant bacteria, a small wound can cause life-threatening infection that can’t be treated with traditional antibiotics.
Antimicrobial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged infectious bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment—naturally occurring enzymes in the body can destroy them within seconds. The Amferia hydrogel technology solves that problem.
Amferia’s breakthrough is the development of a hydrogel platform, encasing the peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed—and lethal to even antibiotic-resistant bacteria. Amferia's antimicrobial hydrogel kills bacteria without harming surrounding body tissue.
“The hydrogel technology we’ve developed enables the safe and stable use of antimicrobial peptides—one of nature’s most powerful defenses—while preventing the enzyme degradation that has historically limited their use,” Rajasekharan said.
Research shows that combining Amferia’s peptide hydrogel platfrom with antibiotics can dramatically amplify their bactericidal effect—up to 64 times stronger—demonstrating its potential to reshape infection management.
At scale, the Amferia approach has the potential to reduce infection rates, lower healthcare costs, and provide new options for treating wounds where conventional antimicrobials are becoming less effective.
Amferia has already entered the animal health segment and signed commercial agreements with leading animal health companies in Europe, to introduce a wound dressing that also kills resistant bacteria and is now expanding into new markets with further partnerships in the pipeline.
In December, 2025, Amferia announced the successful closure of a 3.5-million-euro investment round. The round was over-prescribed and spearheaded by existing owners and new investors, among whom are leading voices in wound care.
Looking Ahead
Amferia continues to expand its product pipeline, invest in research, and collaborate with global partners to redefine how infections are prevented and managed. By stabilizing one of nature’s most effective bacterial defenses, the company offers a transformative platform with the potential to strengthen antibiotic treatments and improve outcomes across healthcare.
Learn more about Amferia
https://www.amferia.com/
https://news.cision.com/amferia-ab/r/new-study-finds-innovative-peptide-hydrogel-restores-the-effectiveness-of-antibiotics-against-drug-r,c4067581
https://news.cision.com/amferia-ab/r/first-product-utilizing-amferia-antimicrobial-technology-launched-in-europe-for-animal-wound-care,c4058570
https://news.cision.com/amferia-ab/r/amferia-wins-red-dot-award-for-innovative-design-addressing-bacterial-infections-and-antibiotic-resi,c4063979
Media Contact
Anand Rajasekharan
CEO & Co-Founder, Amferia
+46 76 298 12 38
anandk@amferia.com
